Oncolytics Biotech® announces research collaboration with Keck School of Medicine
Oncolytics announced a collaboration with the Keck School of Medicine using pelareorep in combination with Keytruda®, Velcade® and dexamethasone, to treat multiple myeloma. This study is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone. May 25, 2018